絞り込み

16532

広告

Comparison of the effects of the three major tyrosine kinase inhibitors as first-line therapy for non-small-cell lung cancer harboring epidermal growth factor receptor mutations.

著者 Tu CY , Chen CM , Liao WC , Wu BR , Chen CY , Chen WC , Hsia TC , Cheng WC , Chen CH
Oncotarget.2018 May 11 ; 9(36):24237-24247.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (24view , 0users)

Full Text Sources

Miscellaneous

Patients with advanced lung adenocarcinoma harboring epidermal growth factor receptor (EGFR)-activating mutations have good response rate and longer progression-free survival (PFS) when treated with the tyrosine kinase inhibitors (TKI) compared with platinum-based chemotherapy. However, studies comparing the effectiveness of these drugs as first-line therapy in such patients are limited.
PMID: 29849936 [PubMed]
印刷用ページを開く Endnote用テキストダウンロード